335 related articles for article (PubMed ID: 22771492)
1. Association with nitric oxide synthase on insulin secretory granules regulates glucokinase protein levels.
Markwardt ML; Nkobena A; Ding SY; Rizzo MA
Mol Endocrinol; 2012 Sep; 26(9):1617-29. PubMed ID: 22771492
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells.
Ding SY; Nkobena A; Kraft CA; Markwardt ML; Rizzo MA
J Biol Chem; 2011 May; 286(19):16768-74. PubMed ID: 21454584
[TBL] [Abstract][Full Text] [Related]
3. Regulation of beta cell glucokinase by S-nitrosylation and association with nitric oxide synthase.
Rizzo MA; Piston DW
J Cell Biol; 2003 Apr; 161(2):243-8. PubMed ID: 12707306
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring glucokinase mutations are associated with defects in posttranslational S-nitrosylation.
Ding SY; Tribble ND; Kraft CA; Markwardt M; Gloyn AL; Rizzo MA
Mol Endocrinol; 2010 Jan; 24(1):171-7. PubMed ID: 19934346
[TBL] [Abstract][Full Text] [Related]
5. Nitric Oxide Activates β-Cell Glucokinase by Promoting Formation of the "Glucose-Activated" State.
Seckinger KM; Rao VP; Snell NE; Mancini AE; Markwardt ML; Rizzo MA
Biochemistry; 2018 Aug; 57(34):5136-5144. PubMed ID: 30053375
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Glucokinase by Intracellular Calcium Levels in Pancreatic β Cells.
Markwardt ML; Seckinger KM; Rizzo MA
J Biol Chem; 2016 Feb; 291(6):3000-9. PubMed ID: 26698632
[TBL] [Abstract][Full Text] [Related]
7. A functional link between glucokinase binding to insulin granules and conformational alterations in response to glucose and insulin.
Rizzo MA; Magnuson MA; Drain PF; Piston DW
J Biol Chem; 2002 Sep; 277(37):34168-75. PubMed ID: 12101177
[TBL] [Abstract][Full Text] [Related]
8. GCK-MODY diabetes as a protein misfolding disease: the mutation R275C promotes protein misfolding, self-association and cellular degradation.
Negahdar M; Aukrust I; Molnes J; Solheim MH; Johansson BB; Sagen JV; Dahl-Jørgensen K; Kulkarni RN; Søvik O; Flatmark T; Njølstad PR; Bjørkhaug L
Mol Cell Endocrinol; 2014 Jan; 382(1):55-65. PubMed ID: 24001579
[TBL] [Abstract][Full Text] [Related]
9. Chronic ethanol consumption-induced pancreatic {beta}-cell dysfunction and apoptosis through glucokinase nitration and its down-regulation.
Kim JY; Song EH; Lee HJ; Oh YK; Park YS; Park JW; Kim BJ; Kim DJ; Lee I; Song J; Kim WH
J Biol Chem; 2010 Nov; 285(48):37251-62. PubMed ID: 20855893
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity.
García-Herrero CM; Galán M; Vincent O; Flández B; Gargallo M; Delgado-Alvarez E; Blázquez E; Navas MA
Diabetologia; 2007 Feb; 50(2):325-33. PubMed ID: 17186219
[TBL] [Abstract][Full Text] [Related]
11. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.
Rees MG; Wincovitch S; Schultz J; Waterstradt R; Beer NL; Baltrusch S; Collins FS; Gloyn AL
Diabetologia; 2012 Jan; 55(1):114-22. PubMed ID: 22038520
[TBL] [Abstract][Full Text] [Related]
12. Insight into the biochemical characteristics of a novel glucokinase gene mutation.
Shen Y; Cai M; Liang H; Wang H; Weng J
Hum Genet; 2011 Mar; 129(3):231-8. PubMed ID: 21104275
[TBL] [Abstract][Full Text] [Related]
13. Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes.
Chow E; Wang K; Lim CKP; Tsoi STF; Fan B; Poon E; Luk AOY; Ma RCW; Ferrannini E; Mari A; Chen L; Chan JCN
Diabetes; 2023 Feb; 72(2):299-308. PubMed ID: 36342518
[TBL] [Abstract][Full Text] [Related]
14. β-Cell glucokinase expression was increased in type 2 diabetes subjects with better glycemic control.
Liu J; Fu H; Kang F; Ning G; Ni Q; Wang W; Wang Q
J Diabetes; 2023 May; 15(5):409-418. PubMed ID: 36942376
[TBL] [Abstract][Full Text] [Related]
15. A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs.
Shammas C; Neocleous V; Phelan MM; Lian LY; Skordis N; Phylactou LA
Metabolism; 2013 Nov; 62(11):1535-42. PubMed ID: 23890519
[TBL] [Abstract][Full Text] [Related]
16. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans.
Peter A; Stefan N; Cegan A; Walenta M; Wagner S; Königsrainer A; Königsrainer I; Machicao F; Schick F; Häring HU; Schleicher E
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1126-30. PubMed ID: 21490074
[TBL] [Abstract][Full Text] [Related]
17. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.
Beer NL; Tribble ND; McCulloch LJ; Roos C; Johnson PR; Orho-Melander M; Gloyn AL
Hum Mol Genet; 2009 Nov; 18(21):4081-8. PubMed ID: 19643913
[TBL] [Abstract][Full Text] [Related]
18. A panel of diverse assays to interrogate the interaction between glucokinase and glucokinase regulatory protein, two vital proteins in human disease.
Rees MG; Davis MI; Shen M; Titus S; Raimondo A; Barrett A; Gloyn AL; Collins FS; Simeonov A
PLoS One; 2014; 9(2):e89335. PubMed ID: 24586696
[TBL] [Abstract][Full Text] [Related]
19. Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young.
Gloyn AL; Odili S; Zelent D; Buettger C; Castleden HA; Steele AM; Stride A; Shiota C; Magnuson MA; Lorini R; d'Annunzio G; Stanley CA; Kwagh J; van Schaftingen E; Veiga-da-Cunha M; Barbetti F; Dunten P; Han Y; Grimsby J; Taub R; Ellard S; Hattersley AT; Matschinsky FM
J Biol Chem; 2005 Apr; 280(14):14105-13. PubMed ID: 15677479
[TBL] [Abstract][Full Text] [Related]
20. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations.
Byrne MM; Sturis J; Clément K; Vionnet N; Pueyo ME; Stoffel M; Takeda J; Passa P; Cohen D; Bell GI
J Clin Invest; 1994 Mar; 93(3):1120-30. PubMed ID: 8132752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
